Imaging Characteristics of Coexisting Primary Pulmonary Carcinoid Tumor and Multiple Myeloma on 18F-FDG and 68Ga-DOTATATE PET/CT

被引：5
|
作者：
Lu, Yang [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Diagnost Imaging, Dept Nucl Med, 1400 Pressler Unit 1483, Houston, TX 77030 USA
来源：
CLINICAL NUCLEAR MEDICINE | 2019年 / 44卷 / 11期
关键词：
multiple myeloma; lung cancer; neuroendocrine tumor; carcinoid; PET; CT; FDG; DOTATATE; NEUROENDOCRINE TUMORS; MANAGEMENT; DIAGNOSIS;
D O I：
10.1097/RLU.0000000000002706
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
A 69-year-old man with recurrent multiple myeloma underwent FDG PET/CT evaluation. A pulmonary nodule without higher-than-background FDG avidity was later biopsied as a low-grade neuroendocrine tumor. On further Ga-68-DOTATATE PET/CT evaluation of patient's neuroendocrine tumor, the lytic myeloma lesions revealed only mild DOTATATE avidity while the primary pulmonary neuroendocrine tumor showed intense DOTATATE uptake. The distinct imaging characteristics of different primary malignancies correlated with their underlying different pathology.
引用
收藏
页码：914 / 915
页数：2
相关论文
共 50 条
  • [21] Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor
    Chan, Mico
    Schembri, Geoffrey Paul
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (02) : 108 - 109
  • [22] Prognostic significance of 68Ga-Pentixafor PET/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET/CT and laboratory results
    Kuyumcu, Serkan
    Isik, Emine Goknur
    Tiryaki, Tarik Onur
    Has-Simsek, Duygu
    Sanli, Yasemin
    Buyukkaya, Fikret
    Ozkan, Zeynep Gozde
    Kalayoglu-Besisik, Sevgi
    Unal, Seher Nilgun
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (10) : 1147 - 1156
  • [23] Multicenter Comparison of 18F-FDG and 68Ga-DOTA-Peptide PET/CT for Pulmonary Carcinoid
    Lococo, Filippo
    Perotti, Germano
    Cardillo, Giuseppe
    De Waure, Chiara
    Filice, Angelina
    Graziano, Paolo
    Rossi, Giulio
    Sgarbi, Giorgio
    Stefanelli, Antonella
    Giordano, Alessandro
    Granone, Pierluigi
    Rindi, Guido
    Versari, Annibale
    Rufini, Vittoria
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (03) : E183 - E189
  • [24] The Diagnostic and Grading Accuracy of 68Ga-DOTATATE and 18F-FDG PET/MR for Pancreatic Neuroendocrine Neoplasms
    Zhou, Jinxin
    Zhao, Runze
    Pan, Yu
    Ju, Huijun
    Huang, Xinyun
    Jiang, Yu
    Jin, Jiabin
    Zhang, Yifan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: A systematic review and meta-analysis
    Jiang, Yuanyuan
    Hou, Guozhu
    Cheng, Wuying
    MEDICINE, 2019, 98 (10)
  • [26] 68Ga-DOTATATE PET/CT in Primary Hepatic Neuroendocrine Tumor
    Gorla, Arun Kumar Reddy
    Basher, Rajender Kumar
    Kaman, Lileshwar
    Bal, Amanjit
    Bhattacharya, Anish
    Mittal, Bhagwant Rai
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (02) : 118 - 120
  • [27] 68Ga-DOTATATE PET/CT Imaging in Carotid Body Tumor
    Gayana, Shankaramurthy
    Mittal, Bhagwant Rai
    Bhattacharya, Anish
    Radotra, Bishan Dass
    Gupta, Ashok K.
    CLINICAL NUCLEAR MEDICINE, 2013, 38 (04) : E191 - E193
  • [28] 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor
    Acar, Emine
    Kaya, Gamze Capa
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (01) : 53 - 54
  • [29] Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in Localization of Tumor Causing Oncogenic Osteomalacia
    Agrawal, Kanhaiyalal
    Bhadada, Sanjay
    Mittal, Bhagwant Rai
    Shukla, Jaya
    Sood, Ashwani
    Bhattacharya, Anish
    Bhansali, Anil
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (01) : E6 - E10
  • [30] The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors A Classification System With Prognostic Impact
    Hayes, Aimee R.
    O'Mahony, Luke Furtado
    Quigley, Ann-Marie
    Gnanasegaran, Gopinath
    Caplin, Martyn E.
    Navalkissoor, Shaunak
    Toumpanakis, Christos
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (01) : 26 - 35
12345